A recent study reveals that people who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds far faster than those who end conventional diet and exercise regimens.
Research printed in a prominent medical journal demonstrates that while overweight people often shed substantial amounts of their total mass while using the jabs, the mass returns at an average rate of 0.8 kg per month after stopping.
"People using such treatments must be aware of the potential of fast rebound weight gain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery implies a return to original mass in about 18 months.
Weighing Approaches
The analysis, which examined 37 of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with other pills.
The team point out that people who shed pounds through diet and exercise generally experience a slower weight regain—around 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Experts suggest the mode of action of the injections is key to understanding the accelerated regain.
The injections imitate a natural hormone called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement results in hunger is unsuppressed, making excessive eating a significant risk."
An Ongoing Issue?
Medical guidelines suggest the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
Many experts contend that, given the likelihood of relapse, the therapy is often long-term.
This view is supported by drug manufacturers, who note that the results "emphasize the chronic character of obesity," similar to managing diseases like diabetes.
Patient Experiences
Users who have stopped the medication describe a intense return of cravings.
"I experienced a trigger flipping and you become extremely hungry," recalled one woman.
This challenge is compounded if individuals have not adopted lasting dietary or behavioural changes during therapy.
Widespread Adoption
Figures show that a significant number of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Adoption is higher among women compared to men.
- The 40s and 50s age group shows the highest usage rates.
- Many obtain the medications through private prescriptions rather than the NHS.
Ultimately, researchers emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a magic solution and long-term success hinges on ongoing behavioural management.